CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators
Preprint
Abstract
Objective Shorter Aβ species might modulate disease progression in Alzheimer’s disease (AD). Here we studied whether Aβ38 levels in cerebrospinal fluid (CSF) are associated with risk of developing AD dementia and cognitive decline. Methods CSF Aβ38 levels were measured in 656 individuals across two clinical cohorts – the Swedish BioFINDER study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Cox regression models were used to evaluate the association between baseline Aβ38 levels and risk of AD dementia in AD-biomarker positive individuals (AD+; determined by CSF P-tau/Aβ42 ratio) with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). Linear mixed effects models were used to evaluate the association between baseline Aβ38 levels and cognitive decline as measured by MMSE in AD+ participants with SCD, MCI or AD dementia. Results In the BioFINDER cohort, high Aβ38 levels were associated with slower decline in MMSE (β = 0.30 points / sd., P = 0.001) and with lower risk of conversion. To AD dementia (HR = 0.83 per sd., P = 0.03). In the ADNI cohort, higher Aβ38 levels were associated with less decline in MMSE (β = 0.27, P = 0.01), but not risk of conversion to AD dementia (P = 0.66). Aβ38 levels in both cohorts remained significantly associated with both outcomes when adjusted for CSF P-tau levels and remained associated with cognition when adjusted for CSF Aβ42 levels. Conclusions Higher CSF Aβ38 levels are associated with lower risk of AD-related changes in two independent clinical cohorts. These findings may have implications for γ-secretase modulators as potential disease-altering therapy.Keywords
All Related Versions
- Published version: Neurology, 98 (9), e958.
This publication has 27 references indexed in Scilit:
- Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s diseaseExpert Opinion on Therapeutic Targets, 2019
- Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?Journal of Biological Chemistry, 2018
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s DiseaseNew England Journal of Medicine, 2018
- Solanezumab: too late in mild Alzheimer's disease?The Lancet Neurology, 2017
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trialsAlzheimer's Research & Therapy, 2016
- Presenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial Alzheimer’s DiseaseNeuron, 2015
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failuresAlzheimer's Research & Therapy, 2014
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's DiseaseNew England Journal of Medicine, 2013
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeuticsNature Reviews Drug Discovery, 2011
- Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40Human Mutation, 2006